Arctic Vision, a clinical-stage biotech company focused on innovative ophthalmology therapies, announced today that it has successfully raised over $100 million in B round financing. The financing was led by Loyal Valley Capital, with participation from Tencent, Octagon Capital, and Dr. Zheng Zhigang, a prominent entrepreneur and the driving force behind New World Group. Existing shareholders Nan Fung Life Sciences, Pivotal bioVenture Partners China, and Morningside Venture Capital also continued to support the company in this round.

CEC Capital Group served as the exclusive financial advisor for Arctic Vision in this transaction.

The proceeds from this financing will continue to support the clinical registration and commercial preparation of the company's product pipeline, the development of its proprietary R&D platform, the continuous introduction of new products, and the expansion of its team.